Role of bevacizumab for treatment-refractory meningiomas: A systematic analysis and literature review.

ABSTRACT:

Background

Meningiomas are the most prevalent primary tumor of the central nervous system (CNS), and although the majority of these neoplasms are classified as benign, nearly one fourth of the lesions display an aggressive profile characterized by pleomorphic histology, high recurrence rates, and overall resistance to standard treatment. Despite the ubiquitous nature of these tumors, no adjuvant therapeutic regimen has been identified which effectively controls disease recurrence and progression after surgery and radiation, leading to a dismal prognosis in this patient population. The primary focus of this research study is, hence, to assess the recently emerging use of bevacizumab, an anti-angiogenic agent, in the treatment of meningiomas. This systematic literature review analyze

SUBMITTER: Franke AJ 

PROVIDER: S-EPMC6057170 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature